Observational studyJournal of cardiothoracic surgery2026
Aortic remodeling after thoracic endovascular repair combined with anti-thrombotic therapy for acute type B aortic dissection.
Observational study in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate the effect of anti-thrombotic (AT) drugs on aortic remodeling and clinical prognosis after thoracic endovascular aortic repair (TEVAR) for acute type B aortic dissection (TBAD).
methodsThis retrospective observational study included consecutive patients with acute TBAD who underwent TEVAR and underwent computed tomography angiography (CTA) preoperatively and during follow-up between January 2012 and September 2023 at the General Hospital of Northern Theater Command. Based on whether AT therapy was administered, the patients were divided into the AT group (patients receiving AT drugs) and the NAT group (patients not receiving AT drugs). Image data were analyzed for the thrombosis status of the false lumen (FL), as well as changes in the maximum diameter of the true lumen (TL), FL, and transaortic lumen (TAL) in the stented thoracic aorta (STA), unstented thoracic aorta (UTA), and abdominal aorta (AA). 12 - month clinical outcomes (major adverse event) were also recorded.
resultsA total of 175 patients with acute TBAD were included in this study. The preoperative FL status of patent, partial thrombosis, and complete thrombosis, respectively, in the STA, UTA, and AA showed no significant differences between the AT and NAT groups. The preoperative mean inner diameters of TL, FL, and TAL, respectively, in the STA, UTA, and AA were also not significantly different between the two groups. Similar to the aforementioned in the preoperative, there were also no significant differences between the two groups at the 12-month follow-up. At 12-month follow-up, FL status (patent vs. completely thrombosed) showed significantly favorable changes compared with preoperative images in the STA, UTA, and AA segments (all P < 0.001). In both the AT and NAT groups, changes in the maximum diameter of TL, FL, and TAL in all segments were statistically significant at 12-month follow-up (all P < 0.001). Regarding diameter changes: TAL expansion was 4.0%, 14.9%, and 53.7% in the STA, UTA, and AA, respectively; TAL stabilization was 62.3%, 36.6%, and 44.6% in the STA, UTA, and AA, respectively; and TAL shrinkage was 33.7%, 48.6%, and 1.7% in the STA, UTA, and AA, respectively. During a 12-month follow-up, 13 patients (7.4%) had a major adverse event. Moreover, the difference between the two groups was not statistically significant (P > 0.05).
conclusionsAmong acute TBAD patients who underwent TEVAR, at the 12 - month follow-up, patients receiving AT drugs had a comparable prognosis in aortic remodeling to those not receiving AT drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.